Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 691 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Headache Clear all
Completed No phase listed Observational

A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.

NCT06467370
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 6, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine

NCT00724815
View directory record Official record
Conditions
Migraine Disorders
Interventions
NP101 - Sumatriptan iontophoretic transdermal patch, Placebo
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 6, 2026, 4:56 AM EDT
Recruiting Not applicable Interventional

A Feasibility Trial of Virtual Reality Neurofeedback for Adolescents With Migraine

NCT07454798
View directory record Official record
Conditions
Migraine, Headache Disorders, Primary
Interventions
Immersive Neurofeedback Self-Regulation Training (INSeRT), Virtual Reality Imagery (No Neurofeedback)
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
10 Years to 16 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 6, 2026, 4:56 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine

NCT02057315
View directory record Official record
Conditions
Migraine Headaches
Interventions
ELS-M11, Placebo
Drug
Lead sponsor
Achelios Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Ann Arbor, Michigan • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 6, 2026, 4:56 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 6, 2026, 4:56 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

NCT02619617
View directory record Official record
Conditions
Cluster Headache - Episodic and Chronic
Interventions
SOM230, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Culver City, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 6, 2026, 4:56 AM EDT
Recruiting No phase listed Observational

Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks

NCT07310290
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Aliso Viejo, California • Naperville, Illinois • Grand Island, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 6, 2026, 4:56 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Droperidol Versus Metoclopramide + Diphenhydramine for the Treatment of Primary Headaches

NCT01406860
View directory record Official record
Conditions
Primary Headaches (Includes Migraines, Tension, Cluster Headaches)
Interventions
Droperidol, Metoclopramide + diphenhydramine
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 64 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 6, 2026, 4:56 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Migraine and CVD Risk in Women

NCT03081390
View directory record Official record
Conditions
Migraine
Interventions
Mixed meal tolerance testing, Skin conductance & cold pressor test, Flow-mediated dilation testing
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 6, 2026, 4:56 AM EDT
Completed No phase listed Observational

Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.

NCT05375097
View directory record Official record
Conditions
Migraine
Interventions
Erenumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 6, 2026, 4:56 AM EDT
Withdrawn Phase 2 Interventional

Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial

NCT05685225
View directory record Official record
Conditions
Migraine
Interventions
Stage 1: Naltrexone/Acetaminophen, Stage 1: Naltrexone, Stage 1: Acetaminophen, Stage1: Placebo, Stage 2: Naltrxone/Acetaminophen high dose, Stage 2: Naltrexone/Acetaminophen medium dose, Stage 2: Naltrxone/Acetaminophen low dose, Stage 2: Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 6, 2026, 4:56 AM EDT
Completed Not applicable Interventional Results available

Treatment for Migraines With an Implantable Device

NCT00286078
View directory record Official record
Conditions
Migraine
Interventions
Precision
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
15
States / cities
Denver, Colorado • Stamford, Connecticut • Augusta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 6, 2026, 4:56 AM EDT
Completed Phase 2 Interventional

An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis

NCT01146509
View directory record Official record
Conditions
Migraine Headache
Interventions
Aricept (donepezil hydrochloride)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
4
States / cities
Chicago, Illinois • Springfield, Missouri • Mount Vernon, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 6, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

NCT03670810
View directory record Official record
Conditions
Migraine
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Huntsville, Alabama • Phoenix, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 6, 2026, 4:56 AM EDT
Recruiting Not applicable Interventional

Determining the Utility of a Behavioral Intervention in Chronic Migraine

NCT05415020
View directory record Official record
Conditions
Migraine, Headache, Migraine Disorders, Chronic Migraine, Lifestyle Factors, Headache Disorders
Interventions
Lifestyle Behavior Protocol, Sham Behavior Protocol
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 6, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

Initiating Early Control of Migraine Pain and Associated Symptoms

NCT04163185
View directory record Official record
Conditions
Migraine
Interventions
AXS-07 (MoSEIC meloxicam and rizatriptan), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Colton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 6, 2026, 4:56 AM EDT
Withdrawn Not applicable Interventional

Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine

NCT00777218
View directory record Official record
Conditions
Migraine
Interventions
propranolol, zonisamide, topiramate
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
8 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 6, 2026, 4:56 AM EDT
Completed Phase 1 Interventional

Acute Treatment of Migraine Using the CEFALY Device

NCT02411513
View directory record Official record
Conditions
Migraine
Interventions
CEFALY
Device
Lead sponsor
Cefaly Technology
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 6, 2026, 4:56 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache

NCT00399243
View directory record Official record
Conditions
Episodic Cluster Headache, Chronic Cluster Headache
Interventions
Sumatriptan 4mg Statdose injection
Drug
Lead sponsor
Diamond Headache Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2009 · Synced Oct 6, 2026, 4:56 AM EDT
Enrolling by invitation Not applicable Interventional

Headache Diary for Migraine Patients

NCT07698249
View directory record Official record
Conditions
Migraine
Interventions
Headache diary
Behavioral
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 6, 2026, 4:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Prospective Survey of Menstrual Migraine & Prevention With Eletriptan

NCT00259649
View directory record Official record
Conditions
Migraine
Interventions
eletriptan
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 6, 2026, 4:56 AM EDT
Completed Phase 3 Interventional Results available

A Study Of Galcanezumab In Participants With Episodic Cluster Headache

NCT02397473
View directory record Official record
Conditions
Episodic Cluster Headache
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 6, 2026, 4:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Inflammatory Markers in Patients With Active Migraine Headaches

NCT00471861
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
Westside Family Medical Center, P.C.
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2011 · Synced Oct 6, 2026, 4:56 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Two Rizatriptan Prescribing Portions for Treatment of Migraine

NCT00397254
View directory record Official record
Conditions
Migraine
Interventions
rizatriptan
Drug
Lead sponsor
Clinvest
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
10
States / cities
Diamond Bar, California • San Francisco, California • Oviedo, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2010 · Synced Oct 6, 2026, 4:56 AM EDT